⌘K
t
Roquefort Therapeutics plc announced on 1 December 2025 that the record date for determining entitlement to new unlisted redeemable non-voting shares (Unlisted RNV Shares) has passed. Holders of ordinary shares and convertible loan notes on the Company's registers as of close of business on 30 November 2025 are entitled to receive these Unlisted RNV Shares.
| Date | 1 Dec 2025 |
| Time | 07:00:13 |
| Category | Miscellaneous |
| ID | 5583J |
1 December 2025
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Determination of Record Date and Entitlement
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted RNV Shares"), the Company confirms that the record date for determining entitlement to the Unlisted RNV Shares has now passed.
Holders of ordinary shares and convertible loan notes who were on the Company's registers as at close of business on 30 November 2025 (the "Record Date") will be entitled to receive Unlisted RNV Shares.
The Unlisted RNV Shares will carry the right to all future commercial benefits arising from the Company's Midkine Investments portfolio, with the ultimate intention of facilitating an in-specie distribution of the Midkine Investments shares to the holders of Unlisted RNV Shares when the Company's balance sheet permits such a distribution in accordance with the Companies Act 2006.
Full details of the entitlement ratio, the exact number of Unlisted RNV Shares to be issued, the crediting process and the anticipated timetable will be set out in a further announcement to be made in due course.
Regulatory Information
This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").
ENDS
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Dr Darrin Disley (Interim MD) |
|
|
SP Angel Corporate Finance LLP (Broker to the Company) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Broker to the Company) Damon Heath |
+44 (0)20 4530 6926
|
|
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper |
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com